This Article Full Text Full Text (PDF) All Versions of this Article: 26/3/624    most recent 01.ATV.0000200136.56716.30v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Samaha, F. F. Articles by Rader, D. J. Search for Related Content PubMed PubMed Citation Articles by Samaha, F. F. Articles by Rader, D. J.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:624.)
© 2006 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome

Frederick F. Samaha; Philippe O. Szapary; Nayyar Iqbal; Monica M. Williams; LeAnne T. Bloedon; Arshneel Kochar; Megan L. Wolfe; Daniel J. Rader

From the Department of Medicine (F.F.S., P.O.S., M.M.W., A.K., D.J.R.), Cardiovascular Division, and the Cardiovascular Institute, University of Pennsylvania Medical Center; The Philadelphia Veterans Affairs Medical Center (F.F.S., N.I., M.M.W.); The Institute for Translational Medicine and Therapeutics (F.F.S., P.O.S., L.T.B., M.L.W., D.J.R.), University of Pennsylvania, Philadelphia. Current affiliation for P.O.S. is Wyeth Research, Collegeville, Pa.

Correspondence to Frederick F. Samaha, Philadelphia VA Medical Center, University and Woodland Avenue, Philadelphia, PA 19104. E-mail rick.samaha{at}med.va.gov

Background— PPAR- agonists improve insulin sensitivity and glycemic control in type 2 diabetes and may reduce atherosclerosis progression. Thus, PPAR- agonists may be an effective therapy for metabolic syndrome. However, the full spectrum of potentially antiatherogenic mechanisms of PPAR- agonists have not been fully tested in nondiabetic patients with metabolic syndrome.

Methods and Results— We performed a prospective, double-blinded, placebo-controlled study of 60 nondiabetic subjects with low high-density lipoprotein cholesterol (HDL-C) level and metabolic syndrome to rosiglitazone 8 mg daily or placebo for 12 weeks. We found no significant effect of rosiglitazone on HDL-C (+5.5% versus +5.8%, P=0.89), and an increase in total cholesterol (+8% versus –1%; P=0.03). Nevertheless, rosiglitazone significantly increased adiponectin (+168% versus +25%; P<0.001), and lowered resistin (–6% versus +4%; P=0.009), C-reactive protein (–32% versus +36%, P=0.002), interleukin (IL)-6 (–22% versus +4%, P<0.001), and soluble tumor-necrosis factor- receptor-2 (–5% versus +7%, P<0.001).

Conclusions— These findings suggest that rosiglitazone, presumably through its PPAR- agonist properties, has direct effects on inflammatory markers and adipokines in the absence of favorable lipid effects. These findings may help explain the mechanism underlying the possible antiatherosclerotic effects of rosiglitazone.

We performed a 12-week, prospective, double-blinded study of 60 nondiabetic subjects with metabolic syndrome randomized to rosiglitazone or placebo. Rosiglitazone had direct effects on inflammatory markers and adipokines in the absence of favorable lipid effects. These findings may underly the possible antiatherosclerotic effects of rosiglitazone.

Key Words: adipocytokines • lipids • inflammation • lipoprotein metabolism • arteriosclerosis

This article has been cited by other articles:

				H. Shen, E. Oesterling, A. Stromberg, M. Toborek, R. MacDonald, and B. Hennig Zinc Deficiency Induces Vascular Pro-Inflammatory Parameters Associated with NF-{kappa}B and PPAR Signaling J. Am. Coll. Nutr., October 1, 2008; 27(5): 577 - 587. [Abstract] [Full Text] [PDF]

				A. Bakhai Adipokines--targeting a root cause of cardiometabolic risk QJM, October 1, 2008; 101(10): 767 - 776. [Abstract] [Full Text] [PDF]

				H. Duez, B. Lamarche, K. D. Uffelman, R. Valero, L. Szeto, S. Lemieux, J. S. Cohn, and G. F. Lewis Dissociation between the Insulin-Sensitizing Effect of Rosiglitazone and Its Effect on Hepatic and Intestinal Lipoprotein Production J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1722 - 1729. [Abstract] [Full Text] [PDF]

				R. R. S. Packard and P. Libby Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction Clin. Chem., January 1, 2008; 54(1): 24 - 38. [Abstract] [Full Text] [PDF]

				A. S. Kelly, A. M. Thelen, D. R. Kaiser, J. M. Gonzalez-Campoy, and A. J. Bank Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus Vascular Medicine, November 1, 2007; 12(4): 311 - 318. [Abstract] [PDF]

				H. Shen, R. MacDonald, D. Bruemmer, A. Stromberg, A. Daugherty, X.-a. Li, M. Toborek, and B. Hennig Zinc Deficiency Alters Lipid Metabolism in LDL Receptor Deficient Mice Treated with Rosiglitazone J. Nutr., November 1, 2007; 137(11): 2339 - 2345. [Abstract] [Full Text] [PDF]

				J-M Gonzalez-Clemente, C Vilardell, M Broch, A Megia, A Caixas, O Gimenez-Palop, C Richart, I Simon, A Martinez-Riquelme, J Arroyo, et al. Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes Eur. J. Endocrinol., July 1, 2007; 157(1): 31 - 38. [Abstract] [Full Text] [PDF]

				A Majuri, M Santaniemi, K Rautio, A Kunnari, J Vartiainen, A Ruokonen, Y A Kesaniemi, J S Tapanainen, O Ukkola, and L Morin-Papunen Rosiglitazone treatment increases plasma levels of adiponectin and decreases levels of resistin in overweight women with PCOS: a randomized placebo-controlled study Eur. J. Endocrinol., February 1, 2007; 156(2): 263 - 269. [Abstract] [Full Text] [PDF]

				G D Norata, M Ongari, K Garlaschelli, S Raselli, L Grigore, and A L Catapano Plasma resistin levels correlate with determinants of the metabolic syndrome Eur. J. Endocrinol., February 1, 2007; 156(2): 279 - 284. [Abstract] [Full Text] [PDF]

				J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]

				S. E. Kahn, S. M. Haffner, M. A. Heise, W. H. Herman, R. R. Holman, N. P. Jones, B. G. Kravitz, J. M. Lachin, M. C. O'Neill, B. Zinman, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy N. Engl. J. Med., December 7, 2006; 355(23): 2427 - 2443. [Abstract] [Full Text] [PDF]

				K. Esposito, M. Ciotola, D. Merante, and D. Giugliano Rosiglitazone Cools Down Inflammation in the Metabolic Syndrome. Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1413 - 1414. [Full Text] [PDF]

				K. Esposito, M. Ciotola, D. Carleo, B. Schisano, F. Saccomanno, F. C. Sasso, D. Cozzolino, R. Assaloni, D. Merante, A. Ceriello, et al. Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome Diabetes Care, May 1, 2006; 29(5): 1071 - 1076. [Abstract] [Full Text] [PDF]